The Tumor Associated Calcium Signal Transducer 2 pipeline drugs market research report outlays comprehensive information on the Tumor Associated Calcium Signal Transducer 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Associated Calcium Signal Transducer 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Triple-Negative Breast Cancer (TNBC). It also reviews key players involved in Tumor Associated Calcium Signal Transducer 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Associated Calcium Signal Transducer 2 pipeline targets constitutes close to 73 molecules. Out of which, approximately 71 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 4, 10, 4, 4, 32, and 15 respectively. Similarly, the universities portfolio in Phase I, and Preclinical comprises 1, and 1 molecule.
Tumor Associated Calcium Signal Transducer 2 overview
Tumor-associated calcium signal transducer 2 (TACSTD2) also known as epithelial glycoprotein-1 (EGP-1) and GA733-1, TACSTD2 belongs to the EpCAM (epithelial cell adhesion molecule) family. TACSTD2 plays a multifaceted role in cancer progression and is often associated with tumor aggressiveness. Its expression is frequently upregulated in various cancers, including colorectal, pancreatic, and breast cancers. As a transmembrane glycoprotein, TACSTD2 is involved in cell adhesion, migration, and signal transduction, contributing to the complex interplay of events that drive cancer development and metastasis. The overexpression of TACSTD2 has been linked to enhanced tumor cell proliferation and resistance to apoptosis, emphasizing its potential as a therapeutic target in cancer treatment.
For a complete picture of Tumor Associated Calcium Signal Transducer 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
